Biology professor shares thoughts on Daraprim
CONNOR HOFFMAN Staff Writer According to the Washington Post, Martin Shkreli, a 32-year-old hedge fund billionaire, became the recent target of enormous criticism. Shkreli achieved this when he decided to raise the price of Daraprim — a new drug his company Turing Pharmaceuticals had purchased — from $13.50 to......